|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:awards
|
gptkb:CDMO_Leadership_Awards
|
|
gptkbp:CEO
|
gptkb:John_Rim
|
|
gptkbp:country
|
gptkb:South_Korea
|
|
gptkbp:expansion
|
Plant 4 completed in 2022
|
|
gptkbp:focus
|
biosimilars
process development
cell line development
fill-finish manufacturing
monoclonal antibody production
|
|
gptkbp:foundedYear
|
2011
|
|
gptkbp:headquartersLocation
|
gptkb:Songdo,_Incheon,_South_Korea
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Samsung Biologics
|
|
gptkbp:industry
|
gptkb:biotechnology
pharmaceuticals
|
|
gptkbp:keyPerson
|
gptkb:John_Rim
gptkb:Kim_Tae-han
|
|
gptkbp:listedOn
|
gptkb:Korea_Exchange
|
|
gptkbp:location
|
gptkb:Songdo,_Incheon,_South_Korea
|
|
gptkbp:notableClient
|
global pharmaceutical companies
|
|
gptkbp:notableInstitution
|
world's largest single-site biopharmaceutical manufacturing facility
|
|
gptkbp:numberOfEmployees
|
over 4,000
|
|
gptkbp:parentCompany
|
gptkb:Samsung_Group
|
|
gptkbp:products
|
biopharmaceutical manufacturing
|
|
gptkbp:revenue
|
over 2 trillion KRW (2022)
|
|
gptkbp:services
|
contract development and manufacturing organization (CDMO)
|
|
gptkbp:stockExchange
|
gptkb:KOSPI
|
|
gptkbp:stockSymbol
|
gptkb:207940.KS
|
|
gptkbp:subsidiary
|
gptkb:Samsung_Bioepis
|
|
gptkbp:website
|
https://www.samsungbiologics.com/
|
|
gptkbp:bfsParent
|
gptkb:Samsung_C&T_Corporation
|
|
gptkbp:bfsLayer
|
5
|